Drugs for Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 380)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Lactulose |
Approved |
Phase 4 |
|
4618-18-2 |
11333 |
Synonyms:
(2S,3R,4S,5R,6R)-2-[(2R,3S,4S,5R)-4,5-Dihydroxy-2,5-bis(hydroxymethyl)oxolan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
(2S,3R,4S,5R,6R)-2-[(2R,3S,4S,5S)-4,5-DIHYDROXY-2,5-BIS(HYDROXYMETHYL)OXOLAN-3-YL]OXY-6-(HYDROXYMETHYL)OXANE-3,4,5-TRIOL
(2S,3R,4S,5R,6R)-2-[(2R,3S,4S,5S)-4,5-DIHYDROXY-2,5-BIS(HYDROXYMETHYL)TETRAHYDROFURAN-3-YL]OXY-6-(HYDROXYMETHYL)TETRAHYDROPYRAN-3,4,5-TRIOL
(2S,3R,4S,5R,6R)-2-[(2R,3S,4S,5S)-4,5-DIHYDROXY-2,5-DIMETHYLOL-TETRAHYDROFURAN-3-YL]OXY-6-METHYLOL-TETRAHYDROPYRAN-3,4,5-TRIOL
(2S,3R,4S,5R,6R)-2-[[(2R,3S,4S,5S)-4,5-DIHYDROXY-2,5-BIS(HYDROXYMETHYL)-3-TETRAHYDROFURANYL]OXY]-6-(HYDROXYMETHYL)TETRAHYDROPYRAN-3,4,5-TRIOL
(2S,3R,4S,5R,6R)-2-{[(2R,3S,4S,5R)-4,5-DIHYDROXY-2,5-BIS(HYDROXYMETHYL)OXOLAN-3-YL]OXY}-6-(HYDROXYMETHYL)OXANE-3,4,5-TRIOL
4-O-b-D-Galactopyranosyl-D-fructofuranose
4-O-b-D-Galactopyranosyl-D-fructose
4-O-beta-delta-Galactopyranosyl-delta-fructofuranose
4-O-beta-delta-Galactopyranosyl-delta-fructose
4-O-beta-D-Galactopyranosyl-D-fructofuranose
4-O-beta-D-Galactopyranosyl-D-fructose
4-O-Β-D-galactopyranosyl-D-fructofuranose
4-O-Β-D-galactopyranosyl-D-fructose
ACILAC
Amivalex
Bifiteral
Cephulac
CEPHULAC SYRUP
CHOLAC
Chronulac
CONSTILAC
|
CONSTULOSE
delta-Lactulose
D-Lactulose
Duphalac
DUPHALAC DRY
E966
ENULOSE
EVALOSE
GENERLAC
HEPTALAC
Lactulosa
Lactulose
LACTULOSE JP17
Lactulosum
LAXILOSE
LAXOSE ORANGE
LEMLAX
Normase
OSMOLAX
PORTALAC
REGULOSE
|
|
2 |
|
Rifaximin |
Approved, Investigational |
Phase 4 |
|
80621-81-4 |
46783403 6436173 |
Synonyms:
(7S,9Z,11S,12R,13S,14R,15R,16R,17S,18S,19Z,21Z)-2,15,17,23,36-Pentahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6-oxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.1,.0,.0,.0,]heptatriaconta-1(35),2,4,9,19,21,23,25(36),26(34),28,30,32-dodecaen-13-yl acetic acid
4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin
NORMIX
Redactiv
RIFACOL
RIFAMYCIN L 105
RIFAMYCIN L 105SV
RIFAXIDIN
Rifaximin
|
RIFAXIMINA
RIFAXIMINE
RIFAXIMINUM
RIFAXIMINUN
TARGAXAN
Xifaxan
XIFAXANTA
XIFAXSAN
|
|
3 |
|
Midodrine |
Approved |
Phase 4 |
|
133163-28-7, 42794-76-3 |
4195 |
Synonyms:
(+-)-2-Amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide
(+-)-2-Amino-N-(b-hydroxy-2,5-dimethoxyphenethyl)acetamide
(+-)-2-Amino-N-(β-hydroxy-2,5-dimethoxyphenethyl)acetamide
(±)-2-amino-N-(β-hydroxy-2,5-dimethoxyphenethyl)acetamide
1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol
2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide
2-Amino-N-(2,5-dimethoxy-b-hydroxyphenethyl)acetamide
2-Amino-N-(2,5-dimethoxy-β-hydroxyphenethyl)acetamide
A-4020 LINZ
Amatine
Cahill may roberts brand OF midodrine monohydrochloride
Christiaens brand OF midodrine monohydrochloride
DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid
DL-N1-(b-Hydroxy-2,5-dimethoxyphenethyl)glycinamid
DL-N1-(Β-hydroxy-2,5-dimethoxyphenethyl)glycinamid
|
Gutron
Midodrin
Midodrina
Midodrine
Midodrine HCL
Midodrine hydrochloride
Midodrine monohydrochloride
Midodrinum
Midon
Monohydrochloride, midodrine
Nycomed brand OF midodrine monohydrochloride
ProAmatine
Shire brand OF midodrine monohydrochloride
ST 1085
ST-1085
|
|
4 |
|
Dexmedetomidine |
Approved, Experimental, Vet_approved |
Phase 4 |
|
86347-14-0, 113775-47-6 |
68602 5311068 |
Synonyms:
(+)-4-((S)-a,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-Α,2,3-trimethylbenzyl)imidazole
(+-)-4-(a,2,3-Trimethylbenzyl)imidazole
(+-)-4-(alpha,2,3-Trimethylbenzyl)imidazole
(+-)-4-(Α,2,3-trimethylbenzyl)imidazole
(+)-MEDETOMIDINE
(±)-4-(α,2,3-trimethylbenzyl)imidazole
(S)-MEDETOMIDINE
Dexdor
Dexdor®|Igalmi® (dexmedetomidine sublingual film)|MPV 1440|Precedex®
DEXMEDETOMIDIN
Dexmedetomidina
DEXMEDETOMIDINE
DEXMÉDÉTOMIDINE
Dexmedetomidine hydrochloride
Dexmedetomidinum
|
Domitor
Hospira brand OF dexmedetomidine hydrochloride
Hydrochloride, dexmedetomidine
Hydrochloride, medetomidine
Levomedetomidine
Medetomidina
Medetomidina [Spanish]
Medetomidine
Medetomidine hydrochloride
Medetomidinum
Medetomidinum [Latin]
MPV 1440
MPV 785
MPV-1440
MPV-785
Precedex
|
|
5 |
|
Midazolam |
Approved, Illicit |
Phase 4 |
|
59467-70-8 |
4192 |
Synonyms:
Buccolam
Buccolam®|Dormicum®|Nayzilam®|USL261 (nasal spray formulation)|Versed®
Dea no. 2884
Dormicum
Hydrochloride, midazolam
Maleate, midazolam
Mezolam
Midazolam
Midazolam base
MIDAZOLAM CIV
|
Midazolam Hcl
Midazolam hydrochloride
Midazolam maleate
Midazolamum
Midazolamum [INN-Latin]
Nayzilam
USL261
USL-261
Versed
|
|
6 |
|
Buprenorphine |
Approved, Illicit, Investigational, Vet_approved |
Phase 4 |
|
52485-79-7, 53152-21-9 |
644073 40400 |
Synonyms:
(−)-buprenorphine
(-)-Buprenorphine
17-Cyclopropylmethyl-4,5a-epoxy-7a-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol
17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol
17-Cyclopropylmethyl-4,5α-epoxy-7α-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol
2-(N-Cyclopropylmethyl-4,5a-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6a-yl)-3,3-dimethyl-2-butanol
2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol
2-(N-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6α-yl)-3,3-dimethyl-2-butanol
2-[3-Cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol
21-Cyclopropyl-7a-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
21-Cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
21-Cyclopropyl-7α-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
ALKS-5461 COMPONENT BUPRENORPHINE
BUPEAZE
BUPLAST
Buprel
Buprenex
Buprenex®|Buvidal®|CAM2038|Sixmo® (buprenorphine hydrochloride)|Subutex®|Temgesic®
Buprenophine
Buprenorfina
Buprenorfina [INN-Spanish]
BUPRENORPHINE
Buprenorphine grünenthal brand
Buprenorphine Hcl
Buprenorphine hydrochloride
Buprenorphinum
Buprenorphinum [INN-Latin]
Buprex
|
BUTEC
BUTRANS
Essex brand OF buprenorphine hydrochloride
Grünenthal brand OF buprenorphine
Grünenthal brand OF buprenorphine hydrochloride
HAPOCTASIN
Hydrochloride, buprenorphine
Key brand OF buprenorphine hydrochloride
PANITAZ
Prefin
PRENOTRIX
Probuphine
Reckitt and colman brand 1 OF buprenorphine hydrochloride
Reckitt and colman brand 2 OF buprenorphine hydrochloride
Reckitt benckiser brand OF buprenorphine hydrochloride
Reckitt brand OF buprenorphine hydrochloride
RELETRANS
RX 6029 m
RX-6029-m
Schering plough brand OF buprenorphine hydrochloride
Schering-plough brand OF buprenorphine hydrochloride
SEVODYNE
SUBLOCADE
Subutex
Temgesic
Temgésic
TEPHINE
TRANSTEC
|
|
7 |
|
Naloxone |
Approved, Vet_approved |
Phase 4 |
|
465-65-6 |
5284596 |
Synonyms:
(-)-Naloxone
(−)-NALOXONE
(-)-naloxone|Kloxxado® (naloxone hydrochloride nasal spray)|l-naloxone|Narcan®|Nyxoid®
[<i>N</i>-allyl-2,3-<sup>3</sup>H]naloxone
17-Allyl-3,14-dihydroxy-4,5a-epoxymorphinan-6-one
17-Allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one
17-Allyl-3,14-dihydroxy-4,5α-epoxymorphinan-6-one
1-N-Allyl-14-hydroxynordihydromorphinone
Abello brand OF naloxone hydrochloride
Abello, naloxone
Boots brand OF naloxone hydrochloride
Bristol myers squibb brand OF naloxone hydrochloride
Bristol-myers squibb brand OF naloxone hydrochloride
Curamed brand OF naloxone hydrochloride
Curamed, naloxon
DBL Naloxone
Dihydride, naloxone hydrochloride
EN 1530 base
endo Brand OF naloxone hydrochloride
Hydrobromide, naloxone
Hydrochloride dihydride, naloxone
Hydrochloride, naloxone
Lamepro brand OF naloxone hydrochloride
L-Naloxone
MRZ 2593 BR
MRZ 2593BR
MRZ 2593-BR
N-Allylnoroxymorphone
|
Nalone
Nalossone
Nalossone [Dcit]
Naloxon curamed
Naloxon ratiopharm
Naloxona
Naloxona [INN-Spanish]
NALOXONE
Naloxone abello
Naloxone HCl
Naloxone hydrobromide
Naloxone hydrochloride
Naloxone hydrochloride dihydride
Naloxone hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-isomer
Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-isomer
Naloxonratiopharm
Naloxon-ratiopharm
Naloxonum
Naloxonum [INN-Latin]
Narcan
Narcanti
Narcon
NSC-70413
Ratiopharm brand OF naloxone hydrochloride
SERB brand OF naloxone hydrochloride
SUBOXONE
United drug brand OF naloxone hydrochloride
|
|
8 |
|
Carvedilol |
Approved, Investigational |
Phase 4 |
|
72956-09-3 |
2585 |
Synonyms:
(+-)-1-(Carbazol-4-yloxy)-3-((2-(O-methoxyphenoxy)ethyl)amino)-2-propanol
14C-Labeled carvedilol
Artist
BM 14.190
BM-14.190
BM-14190
BM-14-190
C07AG02
CARVEDILOL
Carvédilol
Carvedilol hydrochloride
Carvedilol, (-)
Carvedilol, (-)-isomer
Carvedilol, (+)
Carvedilol, (+)-isomer
Carvedilol, (+-)-isomer
Carvedilol, (R)-isomer
Carvedilol, (S)-isomer
Carvedilol, 14C labeled
|
Carvedilol, 14C-labeled
Carvedilolum
Carvedilolum [Latin]
Coreg
COREG CR
Coreg®|DQ 2466|Eucardic®|SKF 105517
Coropres
Dilatrend
DQ 2466
DQ-2466
Eucardic
EUCARDIC 12.5
EUCARDIC 25
EUCARDIC 3.125
EUCARDIC 6.25
Kredex
Querto
SKF 105517
SKF-105517
|
|
9 |
|
Insulin aspart |
Approved |
Phase 4 |
|
116094-23-6 |
16132418 |
Synonyms:
ASPART
ASPART INSULIN
B28-ASPART-INSULIN
B28-ASP-INSULIN
FIASP
FIASP FLEXTOUCH
FIASP PENFILL
INA-X14
INS NOVORAPID
INSULIN ASPART
Insulin aspart protamine
Insulin aspart protamine recombinant
INSULIN ASPART RECOMBINANT
|
INSULIN X14
INSULIN, ASP(B28)
Insulin, aspart protamine, human
Insulin, aspart, human
Insulin,aspart protamine
Insulina asparta
NOVOLOG
NOVOLOG FLEXPEN
NOVOLOG FLEXTOUCH
NOVOLOG INNOLET
NOVOLOG PENFILL
NOVORAPID
|
|
10 |
|
Memantine |
Approved, Investigational |
Phase 4 |
|
41100-52-1, 19982-08-2 |
4054 |
Synonyms:
1,3-Dimethyl-5-adamantanamine
1,3-Dimethyl-5-aminoadamantane
1,3-DIMETHYLAMINOADAMANTANE
1-Amino-3,5-dimethyladamantane
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
AKATINOL
Axura
Axura®|Ebixa®|Namenda®
D-145
DMAA
DRG-0267
Ebixa
Exiba
FP-01
Lundbeck brand OF memantine hydrochloride
|
MARIXINO
Memantin
Memantina
Memantina [INN-Spanish]
MEMANTINE
Memantine [INN]
MEMANTINE HCL
Memantine hydrochloride
Memantinum
Memantinum [INN-Latin]
Merz brand OF memantine hydrochloride
Namenda
NAMENDA XR
NEMDATINE
NSC-102290
SUN-Y7017
VALIOS
|
|
11 |
|
Formaldehyde |
Approved, Vet_approved |
Phase 4 |
|
50-00-0 |
712 |
Synonyms:
Aldeide formica
Fannoform
Formaldehído
Formaldehyd
Formaldehyde
Formaldehyde solution
FORMALIN
Formalina
Formaline
Formalith
Formic aldehyde
|
Formol
Hyperband
Methaldehyde
Methanal
Methyl aldehyde
Methylene glycol
Methylene oxide
Oxomethane
Oxomethylene
Oxymethylene
Paraform
|
|
12 |
|
Valine |
Approved, Nutraceutical |
Phase 4 |
|
72-18-4 |
1182 6287 |
Synonyms:
(2S)-2-Amino-3-methylbutanoate
(2S)-2-Amino-3-methylbutanoic acid
(S)-2-Amino-3-methylbutanoate
(S)-2-Amino-3-methyl-butanoate
(S)-2-Amino-3-methylbutanoic acid
(S)-2-Amino-3-methyl-butanoic acid
(S)-2-Amino-3-methylbutyrate
(S)-2-Amino-3-methylbutyric acid
(S)-a-Amino-b-methylbutyrate
(S)-a-Amino-b-methylbutyric acid
(S)-alpha-Amino-beta-methylbutyrate
(S)-alpha-Amino-beta-methylbutyric acid
(S)-Valine
2-Amino-3-methylbutanoate
2-Amino-3-methylbutanoic acid
2-Amino-3-methylbutyrate
2-Amino-3-methylbutyric acid
DL-Valine
Hval
L Valine
L-(+)-a-Aminoisovalerate
L-(+)-a-Aminoisovaleric acid
|
L-(+)-alpha-Aminoisovalerate
L-(+)-alpha-Aminoisovaleric acid
L-(+)-Α-aminoisovalerate
L-(+)-Α-aminoisovaleric acid
L-a-Amino-b-methylbutyrate
L-a-Amino-b-methylbutyric acid
L-alpha-Amino-beta-methylbutyrate
L-alpha-Amino-beta-methylbutyric acid
L-VAL
L-Valin
L-VALINE
L-Α-amino-β-methylbutyrate
L-Α-amino-β-methylbutyric acid
NSC-76038
Poly(L-val)
Polyvaline
V
Val
Valin
Valina
VALINE
|
|
13 |
|
Cysteine |
Approved, Nutraceutical |
Phase 4 |
|
52-90-4 |
594 5862 |
Synonyms:
(+)-2-AMINO-3-MERCAPTOPROPIONIC ACID
(2R)-2-AMINO-3-MERCAPTOPROPANOATE
(2R)-2-AMINO-3-MERCAPTOPROPANOIC ACID
(2R)-2-AMINO-3-MERCAPTO-PROPANOIC ACID
(2R)-2-AMINO-3-SULFANYLPROPANOATE
(2R)-2-AMINO-3-SULFANYLPROPANOIC ACID
(2R)-2-AMINO-3-SULFANYL-PROPANOIC ACID
(2R)-2-Amino-3-sulphanylpropanoate
(2R)-2-Amino-3-sulphanylpropanoic acid
(R)-(+)-CYSTEINE
(R)-2-AMINO-3-MERCAPTOPROPANOATE
(R)-2-AMINO-3-MERCAPTO-PROPANOATE
(R)-2-AMINO-3-MERCAPTOPROPANOIC ACID
(R)-2-AMINO-3-MERCAPTO-PROPANOIC ACID
(R)-CYSTEINE
2-Amino-3-mercaptopropanoate
2-Amino-3-mercaptopropanoic acid
2-Amino-3-mercaptopropionate
2-Amino-3-mercaptopropionic acid
2-Amino-3-sulfanylpropanoate
2-Amino-3-sulfanylpropanoic acid
2-Amino-3-sulphanylpropanoate
2-Amino-3-sulphanylpropanoic acid
3-MERCAPTO-L-ALANINE
ACETYLCYSTEINE
ALPHA-AMINO-BETA-THIOLPROPIONIC ACID
BETA-MERCAPTOALANINE
B-MERCAPTOALANINE
C
CARBOCYSTEINE
Cisteina
|
CISTEINUM
Cys
Cystein
Cysteine
CYSTEINE HCL
Cysteine hydrochloride
CYSTEINUM
E 920
E920
E-920
E921
Ecolan
FREE CYSTEINE
Half cystine
Half-cystine
Hcys
L Cysteine
L-(+)-CYSTEINE
L-2-AMINO-3-MERCAPTOPROPANOATE
L-2-AMINO-3-MERCAPTOPROPANOIC ACID
L-2-Amino-3-mercaptopropionate
L-2-AMINO-3-MERCAPTOPROPIONIC ACID
L-CYS
L-CYSTEIN
L-Cysteine
L-ZYSTEIN
POLYCYSTEINE
THIOSERINE
Zinc cysteinate
Zystein
|
|
14 |
|
Vitamin A |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
22737-96-8, 68-26-8 |
5280382 445354 |
Synonyms:
(2E,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYLCYCLOHEX-1-EN-1-YL)NONA-2,4,6,8-TETRAEN-1-OL
(ALL-E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAEN-1-OL
11-CIS-RETINOL
11-cis-Vitamin a alcohol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-e)-isomer
all trans Retinol
all-trans-Retinol
ALL-TRANS-RETINYL ALCOHOL
ALL-TRANS-VITAMIN A ALCOHOL
ALPHALIN
Aquasol a
AROVIT
BETA-RETINOL
B-RETINOL
CHOCOLA A
cis-11-Retinol
|
NEPALM
NSC-122759
OLEOVITAMIN A
Retinol
RETINOL (VIT A)
RETINOL ACETATE
RETINOL PALMITATE
Retinolum
RO-A-VIT
TRANS-RETINOL
Vitamin a
VITAMIN A 1
VITAMIN A OIL
VITAMIN A SOLUBILIZED
Vitamin a1
|
|
15 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
16 |
|
Thiamine |
Approved, Investigational, Nutraceutical, Vet_approved |
Phase 4 |
|
70-16-6 |
1130 |
Synonyms:
[<sup>3</sup>H]-thiamine|[<sup>3</sup>H]vitamin B<sub>1</sub>
2-[3-[(4-AMINO-2-METHYL-PYRIMIDIN-5-YL)METHYL]-4-METHYL-1-THIA-3-AZONIACYCLOPENTA-2,4-DIEN-5-YL]ETHANOL
2-[3-[(4-AMINO-2-METHYL-PYRIMIDIN-5-YL)METHYL]-4-METHYL-THIAZOL-5-YL]ETHANOL
3-(4-AMINO-2-METHYL-PYRIMIDIN-5-YLMETHYL)-5-(2-HYDROXY-ETHYL)-4-METHYL-THIAZOL-3-IUM
ANEURIN
ANTIBERIBERI FACTOR
APATE DROPS
BEATINE
BEDOME
BEGIOLAN
BENERVA
BEQUIN
BERIN
BETALIN S
BETAXIN
BETHIAZINE
BEUION
BEVITEX
BEVITINE
BEWON
BIAMINE
BITHIAMIN
BIUNO
BIVATIN
BIVITA
CERNEVIT-12
CLOTIAMINA
ESKAPEN
|
ESKAPHEN
HYBEE
LIXA-BETA
METABOLIN
Mononitrate, thiamine
SLOWTEN
THD
THIADOXINE
THIAMIN
THIAMINAL
THIAMINE
Thiamine mononitrate
THIAMINE(1+)
THIAMINE(1+) ION
THIAMINIUM
Thiaminum
THIAMOL
THIAVIT
TIAMIDON
TIAMINA
TIAMINAL
TROPHITE
VETALIN S
VIB
VINOTHIAM
VITAMIN B 1
VITAMIN B1
VITANEURON
|
|
17 |
|
Ascorbic acid |
Approved, Nutraceutical |
Phase 4 |
|
50-81-7 |
54676860 54670067 5785 |
Synonyms:
(+)-Ascorbate
(+)-Ascorbic acid
(+)-Sodium L-ascorbate
[<sup>14</sup>C]-ascorbic acid
3-keto-L-Gulofuranolactone
3-oxo-L-Gulofuranolactone
AA
Acid, ascorbic
Acid, L-ascorbic
Acide ascorbique
Acido ascorbico
ácido ascórbico
Acidum ascorbicum
Acidum ascorbinicum
Adenex
Allercorb
Antiscorbic vitamin
Antiscorbutic vitamin
arco-Cee
Ascoltin
ASCOR
Ascorb
Ascor-b.i.d.
Ascorbajen
Ascorbate
Ascorbate radical
Ascorbate, ferrous
Ascorbate, magnesium
Ascorbate, sodium
ASCORBIC ACID
Ascorbic acid radical
Ascorbic acid, monosodium salt
Ascorbicab
Ascorbicap
Ascorbicin
Ascorbin
Ascorbinsaeure
Ascorbinsäure
Ascorbutina
Ascorin
Ascorteal
Ascorvit
Cantan
Cantaxin
Catavin C
Ce lent
Cebicure
Cebid
Cebion
Cebione
Cecon
Cee-caps TD
Cee-vite
Cegiolan
Ceglion
Ceklin
Celaskon
Celin
Cell C
Cemagyl
Ce-mi-lin
Cemill
Cenetone
Cenolate
Cereon
Cergona
Cescorbat
Cetamid
Cetane
Cetane-caps TC
Cetane-caps TD
Cetebe
Cetemican
Cevalin
Cevatine
Cevex
Cevi-bid
Cevimin
Ce-vi-sol
Cevital
Cevitamate
Cevitamic acid
Cevitamin
Cevitan
Cevitex
Cewin
Chewcee
|
Ciamin
Cipca
Citriscorb
Citrovit
C-Level
C-Long
Colascor
Concemin
C-Quin
C-Span
C-Vimin
Davitamon C
Di-L-ascorbate, magnesium
Dora-C-500
Duoscorb
e 300
e300
e-300
Ferrous ascorbate
gamma-Lactone L-threo-hex-2-enonate
gamma-Lactone L-threo-hex-2-enonic acid
HiCee
Hybrin
ido-C
Juvamine
Kangbingfeng
Kyselina askorbova
L Ascorbic acid
L(+)-Ascorbate
L-(+)-Ascorbate
L(+)-Ascorbic acid
L-(+)-Ascorbic acid
L-3-Ketothreohexuronic acid lactone
Laroscorbine
L-Ascorbate
L-Ascorbic acid
Lemascorb
Liqui-cee
L-Lyxoascorbate
L-Lyxoascorbic acid
L-threo-Ascorbic acid
L-Xyloascorbate
L-Xyloascorbic acid
Magnesium ascorbate
Magnesium ascorbicum
Magnesium di L ascorbate
Magnesium di-L-ascorbate
Magnorbin
Meri-c
Monodehydroascorbate radical
Monodehydroascorbic acid radical
Natrascorb
Natrascorb injectable
Planavit C
Proscorbin
Redoxon
Ribena
Ronotec 100
Rontex 100
Roscorbic
Rovimix C
Scorbacid
Scorbu C
Scorbu-C
Secorbate
Semidehydroascorbate
Semidehydroascorbic acid
Sodascorbate
Sodium ascorbate
Suncoat VC 40
Testascorbic
VASC
Vicelat
Vicin
Vicomin C
Viforcit
Viscorin
Viscorin 100m
Vitace
Vitacee
Vitacimin
Vitacin
Vitamin C
Vitamina C
Vitamisin
Vitascorbol
Xitix
|
|
18 |
|
Aspartic acid |
Approved, Nutraceutical |
Phase 4 |
|
56-84-8 |
5960 |
Synonyms:
(+)-Aspartate
(+)-Aspartic acid
(+-)-Aspartic acid
(2S)-2-AMINOBUTANEDIOIC ACID
(2S)-2-AMINOSUCCINIC ACID
(2S)-Aspartate
(2S)-Aspartic acid
(L)-Aspartate
(L)-Aspartic acid
(R)-2-Aminosuccinate
(R,S)-Aspartic acid
(S)-(+)-Aspartate
(S)-(+)-Aspartic acid
(S)-2-Aminobutanedioate
(S)-2-Aminobutanedioic acid
(S)-2-Aminosuccinate
(S)-2-Aminosuccinic acid
(S)-Aminobutanedioate
(S)-Amino-butanedioate
(S)-Aminobutanedioic acid
(S)-Amino-butanedioic acid
(S)-Aspartate
(S)-Aspartic acid
[<sup>3</sup>H]-L-aspartate|[<sup>3</sup>H]-L-aspartic acid
2-Amino-3-methylsuccinate
2-Amino-3-methylsuccinic acid
2-Aminosuccinate
2-Aminosuccinic acid
ácido aspártico
Acidum asparticum
alpha-Aminosuccinate
alpha-Aminosuccinic acid
Aminosuccinate
Ammonium aspartate
Asp
Asparagate
Asparagic acid
Asparaginate
Asparaginic acid
Asparatate
ASPARTate
Aspartate magnesium hydrochloride
Aspartate, ammonium
Aspartate, calcium
Aspartate, dipotassium
Aspartate, disodium
Aspartate, magnesium
Aspartate, monopotassium
Aspartate, monosodium
Aspartate, potassium
Aspartate, sodium
|
ASPARTIC ACID
Aspartic acid, ammonium salt
Aspartic acid, calcium salt
Aspartic acid, dipotassium salt
Aspartic acid, disodium salt
Aspartic acid, hydrobromide
Aspartic acid, hydrochloride
Aspartic acid, magnesium (1:1) salt, hydrochloride, trihydrate
Aspartic acid, magnesium (2:1) salt
Aspartic acid, magnesium-potassium (2:1:2) salt
Aspartic acid, monopotassium salt
Aspartic acid, monosodium salt
Aspartic acid, potassium salt
Aspartic acid, sodium salt
Calcium aspartate
D
Dipotassium aspartate
Disodium aspartate
FEMA NO. 3656
H-Asp-OH
Hydrobromide aspartic acid
Hydrochloride aspartic acid
Hydrochloride, aspartate magnesium
L Aspartate
L Aspartic acid
L-(+)-Aspartate
L-(+)-Aspartic acid
L-Aminosuccinate
L-Aminosuccinic acid
L-Asp
L-Asp|L-aspartate
L-Asparagate
L-Asparagic acid
L-Asparaginate
L-Asparaginic acid
L-Asparaginsaeure
L-Asparaginsäure
L-Aspartate
L-Aspartic acid
Magnesiocard
Magnesium aspartate
MG 5 Longoral
MG5Longoral
MG-5-Longoral
Monopotassium aspartate
Monosodium aspartate
NSC-3973
Poly-DL-succinimide
Polysuccinimide
Potassium aspartate
Sodium aspartate
|
|
19 |
|
Ornithine |
Approved, Nutraceutical |
Phase 4 |
|
3184-13-2, 70-26-8 |
6262 |
Synonyms:
(+)-S-ORNITHINE
(2S)-2,5-DIAMINOPENTANOIC ACID
(S)-2,5-DIAMINOPENTANOATE
(S)-2,5-DIAMINOPENTANOIC ACID
(S)-2,5-Diaminovalerate
(S)-2,5-DIAMINOVALERIC ACID
(S)-A,D-DIAMINOVALERATE
(S)-A,D-DIAMINOVALERIC ACID
(S)-a,delta-Diaminovalerate
(S)-a,delta-Diaminovaleric acid
(S)-a,Δ-diaminovalerate
(S)-a,Δ-diaminovaleric acid
(S)-alpha,delta-Diaminovalerate
(S)-ALPHA,DELTA-DIAMINOVALERIC ACID
(S)-ORNITHINE
(S)-Α,δ-diaminovalerate
(S)-Α,Δ-DIAMINOVALERIC ACID
2,5 Diaminopentanoic acid
2,5-Diaminopentanoic acid
5-AMINO-L-NORVALINE
|
L-(-)-ORNITHINE
levo-ornithine
L-Ornithine
ORNITHINE
Ornithine dihydrochloride, (L)-isomer
Ornithine hydrochloride, (D)-isomer
Ornithine hydrochloride, (DL)-isomer
Ornithine hydrochloride, (L)-isomer
Ornithine monoacetate, (L)-isomer
Ornithine monohydrobromide, (L)-isomer
Ornithine monohydrochloride, (D)-isomer
Ornithine monohydrochloride, (DL)-isomer
Ornithine phosphate (1:1), (L)-isomer
Ornithine sulfate (1:1), (L)-isomer
Ornithine, (D)-isomer
Ornithine, (DL)-isomer
Ornithine, (L)-isomer
Ornithinum
Ornitina
|
|
20 |
|
Cathartics |
|
Phase 4 |
|
|
|
21 |
|
Laxatives |
|
Phase 4 |
|
|
|
22 |
|
Polyethylene glycol 3350 |
|
Phase 4 |
|
|
|
23 |
|
Anticoagulants |
|
Phase 4 |
|
|
|
24 |
|
Excitatory Amino Acid Antagonists |
|
Phase 4 |
|
|
|
25 |
|
Hypnotics and Sedatives |
|
Phase 4 |
|
|
|
26 |
|
GABA Modulators |
|
Phase 4 |
|
|
|
27 |
|
Anesthetics |
|
Phase 4 |
|
|
|
28 |
|
Adrenergic alpha-Agonists |
|
Phase 4 |
|
|
|
29 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
30 |
|
Sympathomimetics |
|
Phase 4 |
|
|
|
31 |
|
Omega 3 Fatty Acid |
|
Phase 4 |
|
|
|
32 |
|
Anti-Anxiety Agents |
|
Phase 4 |
|
|
|
33 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
34 |
|
Anesthetics, Intravenous |
|
Phase 4 |
|
|
|
35 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
36 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
37 |
|
Buprenorphine, Naloxone Drug Combination |
|
Phase 4 |
|
|
|
38 |
|
Retinol palmitate |
|
Phase 4 |
|
|
|
39 |
|
Whey Protein |
|
Phase 4 |
|
|
|
40 |
|
Folate |
|
Phase 4 |
|
|
|
41 |
|
Vitamin B9 |
|
Phase 4 |
|
|
|
42 |
|
Trace Elements |
|
Phase 4 |
|
|
|
43 |
|
Vitamin B1 |
|
Phase 4 |
|
|
|
44 |
|
Vitamin B Complex |
|
Phase 4 |
|
|
|
45 |
|
Thiamin |
|
Phase 4 |
|
|
|
46 |
|
Micronutrients |
|
Phase 4 |
|
|
|
47 |
|
Adrenergic alpha-Antagonists |
|
Phase 4 |
|
|
|
48 |
|
Adrenergic alpha-1 Receptor Antagonists |
|
Phase 4 |
|
|
|
49 |
|
Soy Bean |
|
Phase 4 |
|
|
|
50 |
|
Antiparkinson Agents |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 659)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Randomized Trial Comparing The Efficacy of PEG (Polyethylene Glycol) Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy |
Unknown status |
NCT03100513 |
Phase 4 |
Lactulose;Polyethylene Glycol |
2 |
Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy |
Unknown status |
NCT02401490 |
Phase 4 |
Human albumin;Placebo |
3 |
Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Liver Cirrhosis and Minimal Encephalopathy: a Single Center Placebo Control Double Blind Study |
Unknown status |
NCT00896831 |
Phase 4 |
L-ornithine-L-aspartate;placebo |
4 |
Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis |
Unknown status |
NCT02470546 |
Phase 4 |
Metformin;Placebo |
5 |
Therapeutic Efficacy of Oral PEG3350 Plus Lactulose Versus Lactulose Alone in Patients of Acute on Chronic Liver Failure With Overt Hepatic Encephalopathy: A Single Blind Prospective Randomized Controlled Study |
Unknown status |
NCT03987893 |
Phase 4 |
PEG-3350 with Electolytes;Lactulose |
6 |
Randomized Controlled Trial Comparing Effects of Sedation for Upper Gastrointestinal Endoscopy With Propofol Versus Midazolam on Psychometric Tests and Critical Flicker Frequency in Cirrhotics |
Unknown status |
NCT01356121 |
Phase 4 |
Propofol;Midazolam |
7 |
Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy |
Unknown status |
NCT01178372 |
Phase 4 |
Lactulose;Probiotics(VSL#3) |
8 |
Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose |
Unknown status |
NCT01175538 |
Phase 4 |
Lactulose |
9 |
Detection of Silent Atrial Fibrillation aFter Ischemic StrOke (SAFFO) Guided by Implantable Loop Recorder. Multicentre Italian Trial Based on Stroke Unit Network With Paired Cardio-Arrhythmology Units (Italian Neurocardiology Unit Network) |
Unknown status |
NCT02684825 |
Phase 4 |
|
10 |
LOLA in Hepatic Encephalopathy Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate A Phase iv Randomised Double Blind Placebo- Controlled Trial |
Completed |
NCT01847651 |
Phase 4 |
LOLA or placebo |
11 |
Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life |
Completed |
NCT00375375 |
Phase 4 |
Lactulose |
12 |
Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation |
Completed |
NCT00839358 |
Phase 4 |
albumin;Midodrine;Placebo |
13 |
Septic Encephalopathy and Late Cognitive Dysfunction in Patients With Sepsis - the Role of Inflammation |
Completed |
NCT00772096 |
Phase 4 |
n-3 fatty acids |
14 |
Efficacy of Combined Oral L-ornithine-L-aspartate and Oral Lactulose in Patients With Hepatic Encephalopathy |
Completed |
NCT00740142 |
Phase 4 |
L-ornithine-L-aspartate and lactulose;placebo and lactulose |
15 |
Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers |
Completed |
NCT01846455 |
Phase 4 |
2.0mg Buprenorphine/0.5mg Naloxone;Promethazine |
16 |
A Multicenter, Randomized, Open-Label, Active-Controlled, Trial to Evaluate the Safety and Efficacy of Rifaximin 550 mg With and Without Lactulose in Subjects With a History of Recurrent Overt Hepatic Encephalopathy |
Completed |
NCT01842581 |
Phase 4 |
Rifaximin;Lactulose |
17 |
Rifaximin and Its Microbial Resistance as a Secondary Prophylaxis of Hepatic Encephalopathy in Patients With HCV Related Cirrhosis |
Completed |
NCT04736836 |
Phase 4 |
Rifaximin |
18 |
Optimum Thiamine Intervention (OpT In) for Treatment and Prevention of Wernicke-Korsakoff Syndrome (WKS): A Randomised Controlled Trial |
Completed |
NCT02788552 |
Phase 4 |
Thiamine Hydrochloride |
19 |
A Placebo Controlled Single Centre Double Blind Randomised Trial to Investigate the Efficacy of Rifaximin Versus Placebo in Improving Systemic Inflammation and Neutrophil Malfunction in Patients With Cirrhosis and Chronic Hepatic Encephalopathy |
Completed |
NCT02019784 |
Phase 4 |
Rifaximin-α;Placebo Oral Tablet |
20 |
Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy: A Randomized Open Controlled Study |
Completed |
NCT03077217 |
Phase 4 |
Rifaximin |
21 |
Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension |
Completed |
NCT01059396 |
Phase 4 |
propranolol;carvedilol;placebo |
22 |
The Infusion of L-Ornithine L-aspart is as Effective as Nonabsorbable Disaccharides in the Management of Acute Hepatic Encephalopathy. |
Completed |
NCT01041755 |
Phase 4 |
L-ornithine-L-aspartate;Lactose |
23 |
Effect of the Proteins of the Diet in Patients With Cirrhosis and a Prior Episode of Hepatic Encephalopathy. A Randomized Study |
Completed |
NCT00955500 |
Phase 4 |
|
24 |
Effects of the Administration of Albumin in Patients With Cirrhosis and Acute Hepatic Encephalopathy. |
Completed |
NCT00886925 |
Phase 4 |
Albumin;Sodium chloride 0.9% |
25 |
Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial |
Completed |
NCT01722578 |
Phase 4 |
L-ornithine L-aspartate;Placebo |
26 |
Effect of Albumine Infusion in the Prevention of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt |
Completed |
NCT01559519 |
Phase 4 |
Albumin |
27 |
Comparison of Three Different Schemes:Lactulose, L-ornithine L-aspartate, or Rifaximin, Versus Placebo, as Primary Prophylaxis of the Development of Hepatic Encephalopathy After Acute Variceal Bleeding in Cirrhotic Patients |
Completed |
NCT02158182 |
Phase 4 |
Lactulose;L-ornithine L-aspartate;Rifaximin;Placebo |
28 |
The First-day High Dose Vitamin E and Vitamin C in Hypoxic Ischemic Encephalopathy (Following Birth Asphyxia) in Newborns |
Completed |
NCT01743742 |
Phase 4 |
Vitamin E, Vitamin C |
29 |
Randomized Double-blind Placebo-controlled Trial of Memantine Hydrochloride for the Treatment of Childhood-onset Epileptic Encephalopathies |
Completed |
NCT03779672 |
Phase 4 |
Memantine Hydrochloride 10 mg |
30 |
A Randomized, Controlled, Multicentric Trial Comparing Endoscopic Band Ligation Versus Ransjugular Intrahepatic Portosystemic Stent Shunt in Cirrhotic Patients With Recurrent Variceal Bleeding Non Responding to Medical Therapy |
Completed |
NCT00570973 |
Phase 4 |
|
31 |
Comparative Study of Dexmedetomidine-midazolam Combination and Propofol-midazolam Combination for MRI Brain in Paediatric Patient |
Completed |
NCT02776189 |
Phase 4 |
Dexmedetomidine;propofol;Midazolam |
32 |
Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease: Changes in Biomarkers of Oxidative Stress, Profiles of Plasma Amino Acids and Their Derivatives and Brain Function |
Completed |
NCT01662414 |
Phase 4 |
|
33 |
Phase IV, Double Blind, Multi-Center, Randomized, Two-Arm Crossover Study to Compare 0.1 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem and 0.05 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem in MRI of the Brain |
Completed |
NCT02070380 |
Phase 4 |
MultiHance 0.1 mmol/kg;Dotarem;MultiHance 0.05 mmol/kg |
34 |
Phase IV, Double-blind, Multi-center, Randomized, Crossover Study to Compare 0.1 mmol/kg of Prohance® With 0.1 mmol/kg of Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain (TRUTH) |
Completed |
NCT01613417 |
Phase 4 |
gadoteridol;gadobutrol |
35 |
Fenfluramine for the Treatment of Different Types of Developmental and Epileptic Encephalopathies: a Pilot Trial Exploring Epileptic and Non-epileptic Outcomes |
Recruiting |
NCT05232630 |
Phase 4 |
Fenfluramine |
36 |
Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human Encephalopathies |
Recruiting |
NCT02951559 |
Phase 4 |
|
37 |
Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy: a Randomized Controlled Trial |
Recruiting |
NCT05539027 |
Phase 4 |
Branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA);Branched-chain amino acids (BCAA), enriched solution (Aminoleban) |
38 |
Prevention of Hepatic Encephalopathy by Administration of Rifaximin and Lactulose in Patients With Liver Cirrhosis Undergoing TIPS Placement: a Multi-centre Randomized, Double Blind, Placebo Controlled Trial. |
Recruiting |
NCT04073290 |
Phase 4 |
Rifaximin 550 milligram Oral Tablet [XIFAXAN];Placebo oral tablet;Lactulose 667 milligram/milliliter Oral Solution |
39 |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy |
Recruiting |
NCT01846663 |
Phase 4 |
Placebo;Rifaximin |
40 |
Effect of Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Liver Cirrhosis; a Randomized Clinical Trial (PEGHE Trial) |
Recruiting |
NCT04436601 |
Phase 4 |
Polyethylene Glycols;Lactulose |
41 |
Role and Mechanism of Bifidobacterium Triple Viable Capsules in Improving Motor Symptoms in Patients With Mild to Moderate Parkinson's Disease: a Multicenter Randomized Clinical Study |
Recruiting |
NCT04871464 |
Phase 4 |
Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules |
42 |
Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin. |
Terminated |
NCT01842113 |
Phase 4 |
Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo |
43 |
Randomized Double Blind Placebo Controlled Trial of Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage |
Unknown status |
NCT00553423 |
Phase 3 |
Lactulose;Placebo |
44 |
A Multicenter Randomized Controlled Trial of Therapeutic Hypothermia Plus Magnesium Sulphate (MgSO4) Versus Therapeutic Hypothermia Plus Placebo in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy |
Unknown status |
NCT01646619 |
Phase 3 |
Magnesium Sulphate;Placebo |
45 |
A Randomized, Double-blind, Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone Treatment of Overt Hepatic Encephalopathy |
Unknown status |
NCT02464124 |
Phase 2, Phase 3 |
Nitazoxanide;Lactulose |
46 |
Minimal Hepatic Encephalopathy in Pre-hepatic Portal Hypertension Due to Portal Vein Thrombosis in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study. |
Unknown status |
NCT01798329 |
Phase 3 |
|
47 |
Effect of Erythropoietin and Hypothermia on Management of Neonatal Hypoxic Ischemic Encephalopathy |
Unknown status |
NCT03163589 |
Phase 3 |
Erythropoietin;normal saline |
48 |
Role of Citicoline in Treatment of Newborns With Hypoxic Ischemic Encephalopathy |
Unknown status |
NCT03181646 |
Phase 3 |
citicoline |
49 |
Transcranial Direct Current Stimulation (tDCS) as a Potential Adjunct Intervention in Stroke Rehabilitation |
Unknown status |
NCT01414582 |
Phase 2, Phase 3 |
|
50 |
A Multi-Center, Open-Label Trial to Evaluate the Long-Term Safety and Tolerability of Rifaximin 550 mg BID in Subjects With a History of Hepatic Encephalopathy |
Completed |
NCT00686920 |
Phase 3 |
Rifaximin |
|